Curo Biosciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.12 M
- Company Age 5 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -83.63%
- Profit Growth -102.48%
- Ebitda 7.13%
- Net Worth -32.29%
- Total Assets -33.33%
About Curo Biosciences
Curo Biosciences Private Limited (CBPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 14 August 2019 (Five years and five months 27 days old ). Its registered office is in Nagpur, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.12 M, as per Ministry of Corporate Affairs (MCA) records.
Pradnya Mahatme and Shubhendrasingh Thakur serve as directors at the Company.
Company Details
-
Location
Nagpur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U85300MH2019PTC329302
-
Company No.
329302
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Aug 2019
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Curo Biosciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shubhendrasingh Thakur
|
Director | 14-Aug-2019 | Current |
|
Pradnya Mahatme
|
Director | 20-Apr-2022 | Current |
Financial Performance of Curo Biosciences.
Curo Biosciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 83.63% decrease. The company also saw a substantial fall in profitability, with a 102.48% decrease in profit. The company's net worth observed a substantial decline by a decrease of 32.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Curo Biosciences?
In 2023, Curo Biosciences had a public holding of 58.60%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Gdd Experts India Private LimitedPradnya Mahatme is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Curo Biosciences?
Unlock and access historical data on people associated with Curo Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Curo Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Curo Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
